HMP Global October 7, 2022
Health care decision makers are reviewing digital therapeutics with an emphasis on mobile apps, but prior authorization coverage is being provided to a limited number, reported study authors at AMCP Nexus 2022.
To gather insights on digital therapeutics product evaluations, evidence exchange approaches, and formulary coverage and utilization management, researchers conducted a double-blind web-based survey between April 2022 and May 2022, which was completed by 50 respondents.
Per the results, mobile apps (60%) were the most often reviewed digital therapeutics followed by drug-delivery device combinations (44%), and medication adherence platforms (38%) in the past 12 to 18 months.
Researchers reported that coverage benefit was most commonly dependent on the specific product (42%), but mobile apps (30%) and drug delivery device...
Today's Sponsors
Today's Sponsor